Daniel Janney - 27 Feb 2026 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Reporting relationship: Director
Issuer ticker: KRYS
Reported as of: 27 Feb 2026
Net transaction value: -$3,252,824
SEC form: 4
Accepted by SEC: 03 Mar 2026, 18:28:41 UTC
Prior SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Krish Krishnan, as attorney-in-fact for Daniel Janney

Key filing fact

Daniel Janney filed Form 4 for Krystal Biotech, Inc. (KRYS) on 03 Mar 2026.

Key facts

This page summarizes Daniel Janney's Form 4 filing for Krystal Biotech, Inc. (KRYS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 18:28.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: -$3,252,824.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001198325 Primary reporting owner

JANNEY DANIEL

Relationship: Director
Address: C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH
Signature: /s/ Krish Krishnan, as attorney-in-fact for Daniel Janney
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KRYS transaction

Common Stock

Sale

Transaction value: $2,597,481
Shares: -9,430
Change %: -11%
Price: $275.45
Shares after: 75,666
Date: 27 Feb 2026
Ownership: Directly beneficially owned by Alta Bioequities, L.P.
Footnotes: F1, F2, F3

KRYS transaction

Common Stock

Sale

Transaction value: $655,343
Shares: -2,373
Change %: -3.1%
Price: $276.17
Shares after: 73,293
Date: 27 Feb 2026
Ownership: Directly beneficially owned by Alta Bioequities, L.P.
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sale of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan was entered into on November 25, 2025, and will terminate on November 5, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

Footnote F2

The transaction was executed in multiple trades ranging from $275 to $275.986. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Footnote F3

Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Footnote F4

The transaction was executed in multiple trades ranging from $276 to $276.4924. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.